SG11201809237RA - Oxaborole esters and uses thereof - Google Patents

Oxaborole esters and uses thereof

Info

Publication number
SG11201809237RA
SG11201809237RA SG11201809237RA SG11201809237RA SG11201809237RA SG 11201809237R A SG11201809237R A SG 11201809237RA SG 11201809237R A SG11201809237R A SG 11201809237RA SG 11201809237R A SG11201809237R A SG 11201809237RA SG 11201809237R A SG11201809237R A SG 11201809237RA
Authority
SG
Singapore
Prior art keywords
california
international
rule
ave
applicant
Prior art date
Application number
SG11201809237RA
Inventor
Tsutomu Akama
David Scott Carter
Jason S Halladay
Robert T Jacobs
Yang Liu
Jacob J Plattner
Yong-Kang Zhang
Michael John Witty
Original Assignee
Anacor Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anacor Pharmaceuticals Inc filed Critical Anacor Pharmaceuticals Inc
Publication of SG11201809237RA publication Critical patent/SG11201809237RA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/14—Ectoparasiticides, e.g. scabicides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic System
    • C07F5/02—Boron compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic System
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic System
    • C07F5/02—Boron compounds
    • C07F5/027—Organoboranes and organoborohydrides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A61K31/431—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems containing further heterocyclic rings, e.g. ticarcillin, azlocillin, oxacillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 16 November 2017 (16.11.2017) WIPO I PCT omit VIII Hot 0 mu ioo Immo iflo oimIE (10) International Publication Number WO 2017/195069 Al (51) International Patent Classification: C07F 5/02 (2006.01) A61P 33/00 (2006.01) A61K 31/69 (2006.01) (21) International Application Number: PCT/IB2017/052522 (22) International Filing Date: 01 May 2017 (01.05.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/335,565 12 May 2016 (12.05.2016) US (71) Applicant: ANACOR PHARMACEUTICALS, INC. [US/US]; 1020 East Meadow Circle, Palo Alto, California 94303 (US). (72) Inventors: AKAMA, Tsutomu; 933 Berkshire Ave, Sun- nyvale, California 94087 (US). CARTER, David Scott; 1452 La Crosse Dr, Sunnyvale, California 94087 (US). HALLADAY, Jason S.; 16400 Hilow Rd., Los Gatos, California 95032 (US). JACOBS, Robert T.; 1849 Old College Circle, Wake Forest, North Carolina 27587 (US). LIU, Yang; 740 Polaris Ave, Foster City, California 94404 (US). PLATTNER, Jacob J.; 1026 Alvarado Road, Berke- ley, California 94705 (US). ZHANG, Yong-Kang; 5151 Westmont Ave, San Jose, California 95130 (US). WITTY, Michael John; c/o Anacor Pharmaceuticals, Inc., 1020 East Meadow Circle, Palo Alto, California 94303 (US). (74) Agent: WALDRON, Roy F.; Pfizer Inc., 235 East 42nd Street, MS 235/9/S20, New York, New York 10017 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: as to the identity of the inventor (Rule 4.17(i)) as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) Published: — with international search report (Art. 21(3)) N O (57) : The present invention provides oxaborole ester compounds and compositions thereof which are useful to treat diseases 0 associated with parasites, such as Chagas Disease and African Animal Trypanosomosis. (54) Title: OXABOROLE ESTERS AND USES THEREOF
SG11201809237RA 2016-05-12 2017-05-01 Oxaborole esters and uses thereof SG11201809237RA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662335565P 2016-05-12 2016-05-12
PCT/IB2017/052522 WO2017195069A1 (en) 2016-05-12 2017-05-01 Oxaborole esters and uses thereof

Publications (1)

Publication Number Publication Date
SG11201809237RA true SG11201809237RA (en) 2018-11-29

Family

ID=58699201

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201809237RA SG11201809237RA (en) 2016-05-12 2017-05-01 Oxaborole esters and uses thereof

Country Status (31)

Country Link
US (4) US10562921B2 (en)
EP (2) EP3455227A1 (en)
JP (2) JP6715957B2 (en)
KR (2) KR102231489B1 (en)
CN (2) CN109153688A (en)
AR (2) AR108450A1 (en)
AU (2) AU2017263785B2 (en)
BR (2) BR122023022427A2 (en)
CA (1) CA3023490C (en)
CL (2) CL2018003187A1 (en)
CO (1) CO2018012077A2 (en)
CR (2) CR20180502A (en)
DK (1) DK3578562T3 (en)
EA (2) EA036661B1 (en)
EC (2) ECSP18091065A (en)
ES (1) ES2882782T3 (en)
HK (1) HK1258717A1 (en)
HU (1) HUE056320T2 (en)
IL (2) IL262453A (en)
MA (1) MA44968A (en)
MX (2) MX2018013743A (en)
NI (2) NI201801172A (en)
NZ (1) NZ746906A (en)
PE (2) PE20191077A1 (en)
PT (1) PT3578562T (en)
SG (1) SG11201809237RA (en)
TN (2) TN2019000106A1 (en)
TW (1) TWI629279B (en)
UA (2) UA120999C2 (en)
UY (2) UY37236A (en)
WO (1) WO2017195069A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10070649B2 (en) 2013-01-30 2018-09-11 Agrofresh Inc. Volatile applications against pathogens
US11039617B2 (en) 2013-01-30 2021-06-22 Agrofresh Inc. Large scale methods of uniformly coating packaging surfaces with a volatile antimicrobial to preserve food freshness
TW201735792A (en) 2016-03-07 2017-10-16 農業保鮮股份有限公司 Synergistic methods of using benzoxaborole compounds and preservative gases as an antimicrobial for crops
CN109153688A (en) * 2016-05-12 2019-01-04 安纳考尔医药公司 Oxa- boron Polymorphs alkyl ester class and application thereof
JP2021505660A (en) * 2017-11-30 2021-02-18 ボラゲン，インコーポレーテッド Benzoxabolol compounds and their formulations
JP2020180170A (en) * 2019-04-23 2020-11-05 東ソー株式会社 Halogen-containing polyether polyol composition

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4911920A (en) 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
FR2588189B1 (en) 1985-10-03 1988-12-02 Merck Sharp & Dohme LIQUID-GEL PHASE TRANSITION PHARMACEUTICAL COMPOSITION
DE69212850T2 (en) 1991-01-15 1997-03-06 Alcon Lab Inc Use of carrageenan in topical ophthalmic compositions
US5212162A (en) 1991-03-27 1993-05-18 Alcon Laboratories, Inc. Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
GB9411587D0 (en) 1994-06-09 1994-08-03 Zeneca Ltd Compound, composition and use
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
JO3396B1 (en) 2007-06-20 2019-10-20 Anacor Pharmaceuticals Inc Boron-containing small molecules
WO2010045505A1 (en) 2008-10-15 2010-04-22 Anacor Pharmaceuticals, Inc Boron-containing small molecules as anti-protozoal agents
US9493489B2 (en) * 2008-10-15 2016-11-15 Anacor Pharmaceuticals, Inc. Boron-containing small molecules as anti-protozoal agents
AP4039A (en) 2009-08-14 2017-02-28 Daitao Chen Boron-containing small molecules as antiprotozoal agents
US8933018B2 (en) 2011-02-07 2015-01-13 Rempex Pharmaceuticals, Inc. Boron containing polybasic bacterial efflux pump inhibitors and therapeutic uses thereof
CN103857289A (en) 2011-10-07 2014-06-11 先正达参股股份有限公司 Method for protecting useful plants or plant propagation material
AR088669A1 (en) 2011-11-21 2014-06-25 Lilly Co Eli DERIVATIVES OF DIHYDRODIBENZO [C] [1,2] OXABOROL AND DIHYDROISOXAZOL USEFUL FOR THE CONTROL OF ECTOPARASITES
US8669207B1 (en) * 2013-01-30 2014-03-11 Dow Agrosciences, Llc. Compounds and compositions
US9493490B1 (en) 2013-07-22 2016-11-15 Anacor Pharmaceuticals, Inc. Boron-containing small molecules
AU2014305792C1 (en) 2013-08-09 2018-07-05 Anacor Pharmaceuticals, LLC. Tricyclic benzoxaborole compounds and uses thereof
US20170000133A1 (en) * 2013-12-23 2017-01-05 Syngenta Participations Ag Benzoxaborole fungicides
WO2017029289A1 (en) * 2015-08-17 2017-02-23 Syngenta Participations Ag 1-hydroxy-3h-2,1-benzoxaborole derivatives and their use as microbiocides
CN109153688A (en) * 2016-05-12 2019-01-04 安纳考尔医药公司 Oxa- boron Polymorphs alkyl ester class and application thereof

Also Published As

Publication number Publication date
MX2018015410A (en) 2019-05-27
BR112018071931A2 (en) 2019-02-05
HUE056320T2 (en) 2022-02-28
CL2018003187A1 (en) 2019-01-11
CN109503637A (en) 2019-03-22
IL262453A (en) 2018-12-31
CA3023490C (en) 2021-06-08
US20170327519A1 (en) 2017-11-16
AR113543A2 (en) 2020-05-13
CL2018003377A1 (en) 2019-01-11
TW201808968A (en) 2018-03-16
JP6715957B2 (en) 2020-07-01
CA3023490A1 (en) 2017-11-16
UA120999C2 (en) 2020-03-10
PE20191077A1 (en) 2019-08-20
JP2019081770A (en) 2019-05-30
US10562921B2 (en) 2020-02-18
TN2018000351A1 (en) 2020-06-15
CN109153688A (en) 2019-01-04
US20200017531A1 (en) 2020-01-16
US10882872B2 (en) 2021-01-05
PT3578562T (en) 2021-08-05
AU2018264116A1 (en) 2018-12-06
CO2018012077A2 (en) 2018-11-22
BR122018076188A2 (en) 2019-09-10
EP3455227A1 (en) 2019-03-20
AU2018264116B2 (en) 2020-03-12
PE20190119A1 (en) 2019-01-17
EA201892203A1 (en) 2019-04-30
BR122023022427A2 (en) 2023-12-26
US11578087B2 (en) 2023-02-14
AU2017263785A1 (en) 2018-10-25
KR20190005982A (en) 2019-01-16
CN109503637B (en) 2021-03-16
DK3578562T3 (en) 2021-07-12
NI201801171A (en) 2019-04-10
AU2017263785B2 (en) 2019-10-03
ECSP18091065A (en) 2019-07-31
UY37980A (en) 2020-06-30
HK1258717A1 (en) 2019-11-15
NZ746906A (en) 2020-06-26
AR108450A1 (en) 2018-08-22
JP2019520326A (en) 2019-07-18
EA201892475A1 (en) 2019-04-30
ES2882782T3 (en) 2021-12-02
CR20180502A (en) 2018-12-21
NI201801172A (en) 2019-04-10
US20230132298A1 (en) 2023-04-27
KR20190002695A (en) 2019-01-08
UY37236A (en) 2018-01-02
UA121354C2 (en) 2020-05-12
MA44968A (en) 2019-03-20
TN2019000106A1 (en) 2020-10-05
MX2018013743A (en) 2019-05-02
EP3578562A1 (en) 2019-12-11
IL263161A (en) 2018-12-31
WO2017195069A1 (en) 2017-11-16
KR102231489B1 (en) 2021-03-23
KR102243775B1 (en) 2021-04-22
EA036661B1 (en) 2020-12-04
EP3578562B1 (en) 2021-06-23
IL263161B (en) 2022-05-01
US20210101916A1 (en) 2021-04-08
EA034415B1 (en) 2020-02-05
JP6715966B2 (en) 2020-07-01
ECSP19026702A (en) 2019-06-30
CR20180560A (en) 2019-01-25
TWI629279B (en) 2018-07-11

Similar Documents

Publication Publication Date Title
SG11201809237RA (en) Oxaborole esters and uses thereof
SG11201805300QA (en) Heterocyclic compounds as immunomodulators
SG11201907544VA (en) Jak inhibitors containing a 4-membered heterocyclic amide
SG11201811074RA (en) Nant cancer vaccine
SG11201901700UA (en) Biaryl compounds useful as immunomodulators
SG11201803920TA (en) Compounds and compositions useful for treating disorders related to ntrk
SG11201809299QA (en) Formulations of an lsd1 inhibitor
SG11201908604YA (en) Fused imidazo-piperidine jak inhibitor compound
SG11201909963YA (en) Methods for treating dravet syndrome
SG11201903483VA (en) Compositions and methods for treating ezh2-mediated cancer
SG11201809342YA (en) Pyrimidine compounds as jak kinase inhibitors
SG11201810579YA (en) Pyrimidin-2-ylamino-1h-pyrazols as lrrk2 inhibitors for use in the treatment of neurodegenerative disorders
SG11201906436VA (en) Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same
SG11201808222RA (en) Methods of treatment of cholestatic diseases
SG11201804263PA (en) Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitor
SG11201808566WA (en) Polymorphic form of n-{6-(2-hydroxypropan-2-yl)-2-[2-(methylsulphonyl)ethyl]-2h-indazol-5-yl}-6-(trifluoromethyl)pyridine-2-carboxamide
SG11201901063SA (en) Therapeutic agents for neurodegenerative diseases
SG11201803834UA (en) Methods for treating conditions associated with masp-2 dependent complement activation
SG11201806868TA (en) Compositions and methods for protecting against airborne pathogens and irritants
SG11201909837YA (en) Methods for treating lung disorders
SG11201808686VA (en) Synthesis of indazoles
SG11201408808WA (en) Method and system for treatment of biological tissue
SG11201805149XA (en) Compositions comprising 15-hepe and methods of using the same
SG11201811686UA (en) 18f-labeled triazole containing psma inhibitors
SG11201809882XA (en) Pharmaceutical combinations for treating cancer